Longitudinally extensive transverse myelitis (LETM) describes myelitis spanning three or more vertebral segments\(^1,2\) that can cause quadriplegia, marked sensory dysfunction, and respiratory failure. Some patients are unresponsive to conventional immune therapy. We report two cases of severe immune-mediated LETM requiring intensive care admission that failed to respond to high-dose corticosteroids, plasma exchange, intravenous immunoglobulin, and rituximab. Disease cessation and significant recovery was achieved after cyclophosphamide induction. In patients with severe acute immune-mediated LETM who fail to respond to corticosteroids and plasma exchange, cyclophosphamide induction should be considered. This agent and regimen provides a robust immunosuppressive response and can be induced rapidly. Cyclophosphamide effects and supportive evidence are discussed.

Keywords: transverse myelitis, cyclophosphamide, neuroimmunology
doi:10.1017/cjn.2017.201
Can J Neurol Sci. 2017; 44: 736-739

In case 1, a 21-year-old, previously healthy female presented to hospital with a 5-day history of hiccups, abdominal pain, parasthesias, pruritus, and rash. Three weeks prior, she had a brief, non-specific flu-like illness. Other than mild sinus tachycardia and maculopapular rash on her right chest and posterior neck, her systemic examination was normal. Neurologic examination revealed no abnormalities. After admission to internal medicine for suspected viral infection, the neurology consult team recommended a brain and cervical spine magnetic resonance imaging (MRI) scan given her symptoms.

In hospital, abdominal and pelvic ultrasound was non-contributory. Brain MRI was unremarkable, but the suggested spinal MRI was not performed. Over the next 4 days, paresthesias became generalized with accompanying allodynia and urinary retention. On day 5, rapidly ascending symmetric leg weakness developed (Medical Research Council [MRC] Muscle scale, 3 to 4-). Urgent complete spinal MRI demonstrated an edematous T2 hyperintensity extending from the cervical to lumbar spine, with gadolinium enhancement (Figure 1A-D). Repeat brain MRI scan showed new subtle periventricular white matter lesions and a large cervicomedullary junction lesion (Figure 1A-B). Urgent lumbar puncture revealed elevated protein 0.85 g/l, white blood cell count 133.3 × 10^6/L (92% lymphocytes), and oligoclonal banding was positive. Intravenous (IV) methylprednisolone 1 g/day for 6 days
was started on day 8. Positive serum and cerebral spinal fluid aquaporin-4 (AQP4) antibodies confirmed a diagnosis of NMOSD. While on corticosteroids, dysarthria, diplopia, nystagmus, and hypoxic respiratory failure developed, requiring intubation. IV immunoglobulin (2 g/kg total) was added on day 9, but deterioration persisted until quadriplegia and total anesthesia developed. Thus, plasma exchange (PLEX) was initiated on day 13. After eight exchanges with no improvement, rituximab induction (375 mg/m² every week for 4 weeks) was added on day 19. Despite a total of 25 exchanges and rituximab induction, she had no clinical improvement. Repeat MRI scan showed reduction in cord expansion and size of her spinal lesions, but brain imaging was unchanged.

Given her lack of clinical improvement, cyclophosphamide induction was initiated on day 52 whilst continuing PLEX. This consisted of 600 mg/m² IV cyclophosphamide on days 1, 2, 4, 6, and 8 with daily methylprednisolone (modification of the Northeast Cooperative Trial protocol). Although neutropenia necessitated cyclophosphamide discontinuation after two doses, her neurological function improved within 5 days. Two weeks later, she left the intensive care unit (ICU) after a 63-day stay. At that time, she had substantial improvement in arm strength (MRC 4-5), but remained paraplegic. PLEX was discontinued 1 month after cyclophosphamide induction (total of 40 exchanges administered). Maintenance therapy with azathioprine (3-week titration to 150 mg/day divided in three doses) and a slow prednisone taper (60 mg/day titrated down to discontinuation over 10 months) was initiated within weeks of completing cyclophosphamide. After 5 months of inpatient rehabilitation, she regained full arm strength and sufficient leg strength to ambulate with a walker (MRC 3-4). At 11 months, she had MRC 5 power throughout, except for right ankle dorsiflexion (MRC 2).

In case 2, a 19-year-old male with well-controlled celiac disease presented with rapid-onset anesthesia, quadriplegia, and respiratory failure requiring intubation and ICU admission in less than 24 hours. Three days prior, he had a cough and sore throat, but no fever. Three weeks prior, he had an episode of nonbloody diarrhea and a suspected tick bite. On initial assessment, he was intubated, but alert with intact comprehension. He had gaze-evoked nystagmus, mild bifacial weakness, flaccid quadriplegia sparing only the right finger flexors (MRC 1), and a T3 sensory level. Deep tendon reflexes were absent except for 1+ right ankle jerk.

After normal routine serology and cerebral spinal fluid with no evidence of infection, IV methylprednisolone 1 g/day for 5 days was initiated on admission. Brain MRI was unremarkable, but cervical and thoracic spine MRI demonstrated hyperintensity in the central cord and subtle gadolinium enhancement from C2-C5 (Figure 2A-B). Given clinical severity, PLEX was started on day 2. Testing for infectious (including tickborne), metabolic, neoplastic, and autoimmune abnormalities including oligoclonal banding, AQP4, myelin oligodendrocyte glycoprotein, and paraneoplastic antibodies were negative, making the working diagnosis isolated AQP4-LETM.

Repeat MRI (Figure 2C-D) on day 3 of PLEX showed worsening cord edema and increased enhancement. Sensory level on examination had ascended to C4. After 14 plasma exchanges, clinical status remained unchanged, and LETM had spread to C1-C6/7 on MRI (Figure 2E-F), with further increase in enhancement. Given his refractory clinical status and worsening MRI (despite PLEX and high-dose corticosteroids), cyclophosphamide induction (as described in case 1) was completed on day 16. Within a week of induction, motor function began to improve rapidly. Repeat MRI (Figure 2G-H) 2 weeks later showed resolving cord edema and resolution of enhancement. One month later, he was discharged from the ICU and quickly transferred to inpatient neurorehabilitation where he continued a 4-month oral prednisone taper. No further immunosuppressive or immunomodulatory therapy was given. After 5 months of rehabilitation, he was discharged home. He had regained bladder and bowel control, and walked with a walker and ankle foot orthotic. Right deltoid was MRC 2, right bicep MRC 3, bilateral knee flexion MRC 3, left ankle flexion MRC 2, and the remainder of his power examination was MRC 4 or greater.

LETM is a variable entity seen in several conditions, two of which (NMOSD and isolated AQP4-LETM) are presented here. Although most patients respond to first-line therapies of high-dose

---

**Figure 1:** Sagittal MRI scan of the cervical and thoracic spine in case 1. Sagittal T2 of the cervical (A) and thoracic (C) spine shows extensive hyperintensity and areas of fusiform enlargement extending from the lower brainstem throughout the spinal cord and conus medullaris. Some involved areas demonstrate mild patchy enhancement on postgadolinium T1 images (B, D).
corticosteroids and PLEX, a minority of patients do not. In case 1, the NMOSD patient failed high-dose corticosteroids, IVIg, PLEX, and rituximab before cyclophosphamide induction. Rituximab is not known to be an acute rescue therapy for NMOSD; rather, it is considered a longer term disease-modifying therapy. If rituximab were to exert early clinical effects, results would be expected within 1 to 2 weeks as CD20 B-cell depletion occurs within this time frame, which did not occur in case 1. One or both treatments likely contributed to her radiographic improvement, which was seen before cyclophosphamide. Rituximab may have contributed to long-term recovery; however, neither PLEX nor rituximab, both antibody-targeted therapies, provided any acute clinical improvement. In case 2, the isolated LETM patient worsened clinically and radiographically despite high-dose corticosteroids and PLEX.

Although no standardized PLEX duration exists, interstitial immunoglobulin G depletion can be expected within approximately five exchanges. Both patients received much longer PLEX courses without clinical benefit. Both patients had neurologic improvement within days of cyclophosphamide. Their rapid clinical response suggests cyclophosphamide contributed to their acute recovery, expediting ICU discharge and rehabilitation.

Cyclophosphamide has long been used as an off-label rescue therapy for refractory immune-mediated transverse myelitis; however, no randomized control trials exist to provide high level evidence for such use. One study of 122 patients with idiopathic transverse myelitis compared clinical outcomes of corticosteroid treatment, PLEX, cyclophosphamide (750 to 1,000 mg/m²), or PLEX plus cyclophosphamide. Severe cases (American Spinal

Figure 2: Sagittal MRI scan of the cervical spine in case 2. On admission, sagittal MRI of the cervical spine shows hyperintensity of the central spinal cord from C2-C5 levels on T2 images (A) with subtle corresponding enhancement on postgadolinium T1 images (B). After 4 days of high-dose IV methylprednisolone and three plasma exchanges, repeat MRI shows increased edema and hyperintensity on T2 images from C2-C5 (C) with cord expansion, and progressive cord enhancement on postgadolinium images (D). After completing a 5-day course of high-dose IV methylprednisolone and 14 plasma exchanges, repeat MRI shows further extension of cord involvement from C2-C6/7 levels with T2 hyperintensity (E) and increased enhancement on postgadolinium T1 images (F). Two weeks after completion of cyclophosphamide induction, repeat MRI shows resolving cord edema on T2 images (G) and resolution of cord enhancement on postgadolinium T1 images (H).
Injury Association, level A\textsuperscript{11}) who received either cyclophosphamide, or PLEX and cyclophosphamide, had better recovery than those receiving corticosteroids or PLEX alone. However, many patients initially labelled as idiopathic in this study were later found to have underlying autoimmune diseases. Treatment groups were heterogeneous, making comparisons between groups difficult. Nonetheless, this study suggests cyclophosphamide is useful in severe acute LETM cases with varied immunologic backgrounds.

The few reports of cyclophosphamide in NMOSD are conflicting. In a series of four patients with AQP4+ NMOSD, cyclophosphamide treatment of variable doses (500-774 mg/m\textsuperscript{2}) was associated with functional improvement.\textsuperscript{12} Another series of seven patients with NMOSD given pulse cyclophosphamide and methylprednisolone found only one patient was clinically stabilized\textsuperscript{13}; however, only one patient was AQP4+ in this case series because of limited antibody testing availability.

Our two cases suggest high-dose cyclophosphamide is beneficial in acute refractory LETM. Presumably, this is due to its rapid immunosuppressive effect with high-dose induction regimens. Contributory effects of PLEX are possible, but lack of clinical improvement despite multiple exchanges suggests it provided little benefit. Although rituximab likely contributed to long-term recovery in case 1, it is not considered an acute rescue therapy. Rapid improvement shortly after cyclophosphamide induction supports its role the acute setting.

Severe acute LETM requires aggressive treatment as the alternative is often neurologically devastating, with prolonged ICU stays and ventilator dependency. Larger studies are needed to further guide therapeutic decisions and confirm efficacy of specific immune therapies in the critical care setting. However, in patients who fail corticosteroids and PLEX, cyclophosphamide induction should be considered their acute course, not only to promote early neurological recovery, but to reduce ICU admission time and nosocomial complications.

**ACKNOWLEDGMENTS AND FUNDING**

None.

**DISCLOSURES**

JMB has the following disclosures: Novartis, consultant/advisor, honoraria/consulting fees; Sanofi Genzyme, consultant/advisor, honoraria; TEVA, consultant/advisor, honoraria; Biogen, consultant/advisor, honoraria; EMD Serono, consultant/advisor, honoraria. The remaining authors do not have anything to disclose.

**STATEMENT OF AUTHORSHIP**

JMB prepared and wrote case 2 as well as the abstract, introduction, discussion, and prepared revisions. SC prepared and wrote case 1, and contributed to parts of the written discussion. JMB guided the selection of appropriate patients and oversaw revisions. All other authors offered their expertise and contributed to editing.

**REFERENCES**